Primary Immunodeficiencies — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Feasibility of thermal dose painting during magnetic nanoparticle thermal therapy: a computational analysis.
Pawar Shreeniket et al. — International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41813594/
- 2.
Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer.
Choudhury Pritha Roy et al. — Molecular therapy. Oncology (17 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42358377/
- 3.
Molecular investigation of
Tahmasebi Ashtiani Zahra et al. — New microbes and new infections (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42238847/
- 4.
Molecular and functional consequences of the Cdc42 C81Y mutation in immune-associated malignancy.
Chong Chien Fung et al. — Archives of biochemistry and biophysics (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42173300/
- 5.
Adipocyte-rich microenvironment promotes TNBC progression through SIRT6-associated ACSL5 dysregulation and lipid storage-associated phenotypes.
Li Yingnan et al. — Journal of experimental & clinical cancer research : CR (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42387350/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Immunodeficiencies
Primary immunodeficiencies are a diverse group of over 450 genetic conditions that impair the immune system. Common variable immunodeficiency (CVID) is the most prevalent in adults. Many are significantly underdiagnosed. Immunoglobulin replacement therapy is the mainstay of treatment for antibody deficiencies.
Most Recent Research
BACKGROUND: Spatially confined magnetic nanoparticle thermal therapy (SC-MNTT) can improve the tumor coverage index (CI) when the magnetic field-free region (FFR) is manually steered. However, static steering demands significant time and expertise from experienced control engineers during treatment planning. OBJECTIVE: This study presents a computational framework for automated, dynamic FFR steering combined with real-time tumor boundary temperature control to enhance magnetic nanoparticle thermal therapy (MNTT) for cancer therapy. The framework also supports controlled MNTT treatment planning. METHOD: We integrated the Pennes bioheat transfer equation with a proportional-integral-derivative (PID) controller to maintain the maximum tumor boundary temperature at 46 °C. The magnetic nanoparticle (MNP) heat source was divided into four subdomains to simulate SC-MNTT. A fuzzy logic controller automatically selected the FFR based on four-point temperature measurements and corresponding thermal dose, aiming to maximize CI. We examined the influence of key treatment parameters: maximum treatment temperature (60 or 80 °C), MNP distribution (uniform or Gaussian), sensor noise, and MNP position relative to the tumor center. RESULTS: Automated dynamic FFR steering increased CI by ∼25-35%, depending on these parameters. The highest CI occurred at a maximum treatment temperature of 80 °C with a uniform MNP distribution. Sensor noise had minimal effect, while minimal offset between the MNP position and tumor center was essential for maximizing CI. CONCLUSION: The proposed fuzzy logic-based dynamic FFR steering may reduce reliance on expert control engineers for SC-MNTT treatment planning. Future work will focus on pre-clinical implementation and experimental validation of the control system.
Common Questions
What is Primary Immunodeficiencies?
Primary immunodeficiencies are a diverse group of over 450 genetic conditions that impair the immune system. Common variable immunodeficiency (CVID) is the most prevalent in adults. Many are significantly underdiagnosed. Immunoglobulin replacement therapy is the mainstay of treatment for antibody deficiencies.
How many clinical trials are available for Primary Immunodeficiencies?
RareWays currently indexes 167 clinical trials for Primary Immunodeficiencies, of which 29 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Primary Immunodeficiencies come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Primary Immunodeficiencies.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.